MedPath

ABRILADA

ABRILADA

Approved
DIN Number

02511053

Drug Class

Human

Market Date

Mar 7, 2022

Company
HC

Pfizer Canada Ulc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02511053
AIG Number0150364003
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription ,  Schedule D
A
ATC Code
L04AB04 ADALIMUMAB
Product Specifications
Dosage FormSolution
Route of AdministrationSubcutaneous
AHFS Classification90:24.16.92
Health Canada Classification

ACTIVE INGREDIENTS (1)

ADALIMUMABActive
Strength: 40 MG / 0.8 ML
Monograph: ADALIMUMAB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.